Lefitolimod vs standard of care (SOC) for patients with metastatic colorectal cancer (mCRC) responding to first-line standard treatment: Results from the randomized phase III IMPALA trialDavid Cunningham, Dirk Arnold, Eric Van Cutsem et al.|Annals of Oncology|2019Cited by 6
Patient characteristics after completion of recruitment from the phase 3 IMPALA study with lefitolimod in metastatic colorectal carcinomaDavid Cunningham, Dirk Arnold, Eric Van Cutsem et al.|Annals of Oncology|2017Cited by 2